STOCK TITAN

Merus to Participate in Upcoming Investor Conferences

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

On February 1, 2021, Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in upcoming investor conferences. Key events include the Guggenheim Healthcare Talks 2021 Oncology Days on February 12, LifeSci Partners Precision Oncology Day on February 17, and the 2021 SVB Leerink Global Healthcare Conference on February 26. Webcasts of the presentations will be accessible via the Company’s Investors page, with archived versions available for a limited time.

Loading...
Loading translation...
Argus Session date unavailable
-3.71% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was -3.71%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:

Guggenheim Healthcare Talks 2021 Oncology Days (Fireside chat): Friday, Feb. 12 at 10:30-10:55 a.m. ET

LifeSci Partners Precision Oncology Day (Presentation): Wednesday, Feb. 17 at 10:30-10:55 a.m. ET

2021 SVB Leerink Global Healthcare Conference (Presentation): Friday, Feb. 26 at 8:40-9:10 a.m. ET

The live webcasts of the presentations will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and
https://twitter.com/MerusNV.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the upcoming conferences where Merus N.V. (MRUS) CEO will speak?

Merus N.V. CEO Bill Lundberg will speak at the Guggenheim Healthcare Talks on February 12, LifeSci Partners Precision Oncology Day on February 17, and the SVB Leerink Global Healthcare Conference on February 26.

When is the Guggenheim Healthcare Talks 2021 Oncology Days conference?

The Guggenheim Healthcare Talks 2021 Oncology Days conference will take place on February 12, 2021, at 10:30 a.m. ET.

How can I access the presentations from Merus N.V. (MRUS)?

Presentations from Merus N.V. can be accessed via live webcasts on the Company’s Investors page and will also be available as archived versions for a limited time.

What type of company is Merus N.V. (MRUS)?

Merus N.V. is a clinical-stage oncology company developing innovative bispecific and trispecific antibody therapeutics, known as Multiclonics.

What is the focus of Merus N.V.'s research?

Merus N.V. focuses on developing full-length multispecific antibodies aimed at treating various types of cancer.

Keep reading